Curriculum Vitaes
Profile Information
- Affiliation
- Associate Professor, Department of Respiratory Medicine, Fujita Health University School of Medicine
- Degree
- Doctor of Philosophy(Medical Science)(Jan, 2010, Nagoya University)
- Contact information
- gotoyasu
fujita-hu.ac.jp - J-GLOBAL ID
- 201501020248290142
- researchmap Member ID
- 7000012732
Research Areas
1Research History
9-
Jul, 2018 - Jul, 2025
-
Apr, 2014 - Jun, 2018
-
Jun, 2009 - Mar, 2014
-
Apr, 2008 - May, 2009
Education
2-
Apr, 2004 - Mar, 2008
-
Apr, 1993 - Mar, 1999
Committee Memberships
5-
Apr, 2022 - Present
-
Apr, 2022 - Present
-
Mar, 2019 - Present
-
Apr, 2018 - Present
-
Apr, 2019 - Mar, 2022
Major Papers
251-
Nature genetics, 57(1) 65-79, Jan, 2025
-
BMC pulmonary medicine, 24(1) 632-632, Dec 26, 2024
-
Clinical cancer research : an official journal of the American Association for Cancer Research, 31(6) 1127-1141, Nov 4, 2024
-
Cancer research and treatment, 57(2) 412-421, Oct 25, 2024
-
Japanese journal of clinical oncology, 54(10) 1084-1092, Aug 19, 2024
-
Targeted oncology, 19(3) 423-433, May, 2024
-
日本呼吸器学会誌, 13(増刊) 190-190, Mar, 2024
-
Respiration; international review of thoracic diseases, 103(4) 171-176, Feb 22, 2024
-
Exploration of targeted anti-tumor therapy, 5(4) 826-840, 2024Despite innovative advances in molecular targeted therapy, treatment strategies using immune checkpoint inhibitors (ICIs) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) have not progressed significantly. Accumulating evidence suggests that ICI chemotherapy is inadequate in this population. Biomarkers of ICI therapy, such as programmed cell death ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs), are not biomarkers in patients with EGFR mutations, and the specificity of the tumor microenvironment has been suggested as the reason for this. Combination therapy with PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors is a concern because of its severe toxicity and limited efficacy. However, early-stage NSCLC may differ from advanced-stage NSCLC. In this review, we comprehensively review the current evidence and summarize the potential of ICI therapy in patients with EGFR mutations after acquiring resistance to treatment with EGFR-tyrosine kinase inhibitors (TKIs) with no T790M mutation or whose disease has progressed on osimertinib.
-
Frontiers in immunology, 15 1348034-1348034, 2024
-
Frontiers in immunology, 15 1399889-1399889, 2024
-
Therapeutic advances in respiratory disease, 18 17534666241254980-17534666241254980, 2024
-
Targeted oncology, 18(6) 915-925, Oct 30, 2023
-
European journal of cancer (Oxford, England : 1990), 195 113373-113373, Oct 22, 2023 Peer-reviewed
-
肺癌, 63(5) 427-427, Oct, 2023
-
Targeted Oncology, 18(5) 657-665, Aug 23, 2023
-
JAMA network open, 6(7) e2322915, Jul 3, 2023 Peer-reviewed
-
Cancer medicine, 12(15) 15955-15969, Jun 23, 2023
-
気管支学, 45(Suppl.) S237-S237, Jun, 2023
-
Thorax, 78(8) 784-791, Apr 3, 2023 Peer-reviewed
-
日本呼吸器学会誌, 12(増刊) 165-165, Mar, 2023
-
日本呼吸器学会誌, 12(増刊) 206-206, Mar, 2023
-
日本呼吸器学会誌, 12(増刊) 168-168, Mar, 2023
-
Cancer science, 114(2) 606-618, Feb, 2023
-
Cancer immunology, immunotherapy : CII, 72(6) 1699-1707, Jan 9, 2023
-
The oncologist, 27(11) 903-e834-E834, Nov 3, 2022
-
Clinical lung cancer, 23(7) 585-592, Nov, 2022
-
JTO clinical and research reports, 3(9) 100388-100388, Sep, 2022
-
Translational lung cancer research, 11(9) 1847-1857, Sep, 2022
-
Clinical cancer research : an official journal of the American Association for Cancer Research, 28(20) 4402-4409, Aug 18, 2022
-
Fujita medical journal, 8(1) 17-24, Feb, 2022OBJECTIVE: The prevalence of obstructive sleep apnea (OSA) in Japan is 9% among males and 3% among females. Up to 2.5 million patients are estimated to suffer from the disease, but limited number of facilities are capable of carrying out polysomnography (PSG), leaving more than 80% of these individuals are undiagnosed. In recent years, the development of new portable sleep monitoring (PMs) devices has been remarkable. We evaluate the correlation between the results of the LS-140 PMs device (Fukuda Denshi Tech Co. Ltd.), released in 2017, and those of PSG. METHODS: We obtained contemporaneous data from the same patients by equipping 58 patients with PMs (LS-140) devices while they underwent PSG. Our primary outcome was Case 2 of the intraclass correlation coefficient (ICC), i.e., the ICC (2.1). And we used a Bland-Altman analysis to compare the apnea-hypopnea index (AHI) given by PSG and the respiratory event index (REI) given by LS-140 and examined the sensitivity and specificity of the REI relative to the AHI in the diagnosis of OSA. We also carried out the same comparison but in terms of the presence or absence of periodic limb movements (PLMs). RESULTS: The ICC (2.1) between The REI and the AHI was 0.944, a rather high value (p<0.0001). The mean difference between AHI and REI values was -3.6 (p<0.0001), indicating a negative fixed bias. Sensitivity may decrease in groups with PLMs. CONCLUSION: The REI and the AHI are highly correlated, giving LS-140 sufficient diagnostic sensitivity and specificity to screen for OSA.
-
Journal of cancer research and clinical oncology, 148(11) 2985-2994, Nov 26, 2021
-
Journal of cancer research and clinical oncology, 148(9) 2437-2446, Sep 12, 2021
-
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 16(9) 1523-1532, Sep, 2021
-
Biological & pharmaceutical bulletin, 44(9) 1280-1285, Sep 1, 2021
-
Lung cancer (Amsterdam, Netherlands), 161 26-33, Aug 31, 2021
-
TRANSLATIONAL LUNG CANCER RESEARCH, 10(8) 3582-3593, Aug, 2021
-
Allergology international : official journal of the Japanese Society of Allergology, 70(3) 401-403, Jul, 2021
-
BMC pulmonary medicine, 21(1) 181-181, May 29, 2021
Misc.
484-
日本呼吸器学会誌(Web), 14, 2025
-
日本呼吸器学会誌(Web), 14, 2025
-
日本呼吸器学会誌(Web), 14, 2025
-
日本呼吸器学会誌(Web), 14, 2025
-
日本臨床腫瘍学会学術集会(CD-ROM), 22nd, 2025
-
日本臨床腫瘍学会学術集会(CD-ROM), 22nd(増刊) 285-285, 2025
-
日本臨床腫瘍学会学術集会(CD-ROM), 22nd, 2025
-
日本臨床腫瘍学会学術集会(CD-ROM), 22nd, 2025
-
日本臨床腫瘍学会学術集会(CD-ROM), 22nd, 2025
-
日本臨床腫瘍学会学術集会(CD-ROM), 22nd, 2025
-
日本臨床腫瘍学会学術集会(CD-ROM), 22nd, 2025
-
日本臨床腫瘍学会学術集会(CD-ROM), 22nd, 2025
-
日本移植学会総会(Web), 61st(Supplement) 388-388, 2025【背景】肺移植術後の急性細胞性拒絶反応(ACR)は移植肺の機能低下に影響を与える重要な合併症である。ACRの診断には通常経気管支肺生検(TBLB)による病理組織学的検査を施行するが、TBLBにより得られる検体の小ささや挫滅のため診断精度は限定的とされる。近年、より大きな検体採取が可能な経気管支クライオ肺生検(TBLC)の有用性が報告されているが、ACRに対してTBLCを施行したという報告は少ない。【症例】49歳、男性。特発性間質性肺炎に対してX年に脳死下両肺移植術を施行した。術後50日頃から咳、痰症状が出現し、同時に肺機能低下も認めたため、ACRを疑って気管支鏡検査を施行した。右B8よりクライオ生検(2検体採取)を施行し、1検体においては肺血管と周囲に明らかな炎症細胞浸潤を認めず、もう1検体には細気管支と周囲に軽度の炎症細胞浸潤を認めたため、国際心肺移植学会が定めるGrade B1R(Low grade)のACRに矛盾しない病理所見と診断した。治療としてステロイドパルスからステロイドを漸減して、徐々に1秒量の上昇を認めた。【考察】肺移植術後のACRの診断にTBLCが有用であった1例を経験した。海外からはTBLBと比較して、TBLCが診断率を向上させるとする報告もあり、今後TBLCはACR診断のための有用な選択肢になり得ると考える。
-
気管支学(Web), 47(Suppl), 2025
-
CANCER RESEARCH, 84(6), Mar 15, 2024
Books and Other Publications
4Presentations
457Professional Memberships
13Research Projects
1-
医学研究・健康増進活動等助成, 一般財団法人 愛知健康増進財団, Apr, 2020 - Mar, 2021
教育方法・教育実践に関する発表、講演等
2-
件名(英語)第一回研修医のための呼吸器セミナー開始年月日(英語)2018/02/03終了年月日(英語)2018/02/03概要(英語)東海4県の医学系大学が集まり、初期研修医向けの呼吸器セミナーを開催
-
件名(英語)第二回研修医のための呼吸器セミナー(主幹)開始年月日(英語)2019/02/02終了年月日(英語)2019/02/02概要(英語)呼吸器学会東海支部主催で初期研修医向けの呼吸器セミナーを開催(当大学が主幹で主催した)